投資概要
第三季度公司主營業務繼續保持較快增長，醫藥工業與醫藥零售增長維持高速，醫藥分銷平穩增長。我們維持目標價24港元，“買入”評級。(現價截至10月26日)
Graduated from Hong Kong Polytechnic University, Master of Finance (Investment Management). Possess bachelor degree majoring in Financial Management from Southwestern University of Finance and Economics. Focus on industry prospect and corporate fundamentals to explore investment value and cover pharmaceutical and consumer industry.
